Effects of treatment of COVID-19 with convalescent plasma in 25 B-cell depleted patients

Clin Infect Dis. 2021 Jul 22;ciab647. doi: 10.1093/cid/ciab647. Online ahead of print.


25 B-cell depleted patients (24 following anti-CD19/20 therapy) diagnosed with COVID-19, had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. 21 (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.

Keywords: B-cell depletion; COVID-19; SARS-CoV-2; convalescent plasma; immunodefiency.